Projet INsTRuCT (Horizon 2020, appel à projets 2019)
Action : Doctoral Networks
Panel : Life Sciences
Statut du projet : SIGNED

Cell therapy is an active area of immunological research and represents a highly innovative and rapidly expanding sector of pharmaceutical industry. The INsTRuCT Consortium answers an unmet need in the field for postdoctoral researchers experienced in scientifically excellent research and cell therapy development. INsTRuCT draws upon complementary expertise of its academic and industrial partners to offer a unique research and training programme. INsTRuCT proposes 15 distinctive research projects based at European companies or universities recognized for their scientific achievements and innovation. INsTRuCT is structured to promote interdisciplinary and intersectoral cooperation between partners, thereby accelerating pharmaceutical development and clinical application of novel myeloid regulatory cell (MRC)-based therapies. INsTRuCT is a primarily research-based training programme, which will be complemented by theoretical and practical training opportunities. INsTRuCT will encourage a translational view of research, which will be reinforced by intersectoral secondments. Teaching transferrable and communication skills is a high priority for INsTRuCT. ESR will gain a comprehensive overview of the drug development process in Europe as it applies to cell-based therapies; hence, INsTRuCT’s graduates will be fitted for future roles as innovative leaders in the field. INsTRuCT will strengthen interactions between cooperating research groups at junior and senior levels, thereby promoting dissemination of standardized research approaches and data-sharing. Overall, INsTRuCT constitutes an original research and training concept that responds to the specific needs of a growing sector for postdoctoral scientists trained in Basic Immunology and cell therapy development. Consequently, INsTRuCT has a very high impact potential, both in terms of its scientific and technical advancements, and its future contribution to innovation and economic development within the European Union.

Mots clés : cell based therapy, atmp, solid organ transplantation, immunological regulation, mononuclear phagocyte, dendritic cell, macrophage, pharmacokinetics, pharmacodynamics

Participants :
- Miltenyi Biotec (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 277365.05 €
- CERCA Institution (Espagne) — Partner, beneficiary, Recherche, subvention : 250904.88 €
- Cimaas bv (Pays-Bas) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 191836.59 €
- Newcastle University (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 606345.12 €
- Istituti di Ricovero e Cura a Carattere Scientifico (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 261499.68 €
- University of Antwerp (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 245640.0 €
- Nantes Université (France) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274802.04 €
- Sanquin (Pays-Bas) — Partner, beneficiary, Recherche, subvention : 265619.88 €
- University of London (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 227379.42 €
- University Hospital Regensburg (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 624949.1 €
- Charité - Universitätsmedizin Berlin (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 252788.4 €
- Trinity College Dublin (Irlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 274684.32 €
- Miltenyi Biotec (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 0.0 €
- Ministry of Health (Espagne) — Partner, beneficiary, Recherche, subvention : 250904.88 €